Home/Filings/4/0001209191-20-004301
4//SEC Filing

Currie Mark G 4

Accession 0001209191-20-004301

CIK 0001446847other

Filed

Jan 20, 7:00 PM ET

Accepted

Jan 21, 5:23 PM ET

Size

9.1 KB

Accession

0001209191-20-004301

Insider Transaction Report

Form 4
Period: 2020-01-16
Currie Mark G
Chief Scientific Officer
Transactions
  • Exercise/Conversion

    Class A Common Stock

    2020-01-16$10.02/sh+8,888$89,058558,160 total
  • Exercise/Conversion

    Employee Stock Option (Right to Buy)

    2020-01-168,8880 total
    Exercise: $10.02Exp: 2020-02-02Class A Common Stock (8,888 underlying)
  • Sale

    Class A Common Stock

    2020-01-16$12.80/sh8,888$113,766549,272 total
Footnotes (3)
  • [F1]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  • [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.74 to $12.91, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F3]This option, granted as an annual performance award, is presently exercisable in full.

Issuer

IRONWOOD PHARMACEUTICALS INC

CIK 0001446847

Entity typeother

Related Parties

1
  • filerCIK 0001478244

Filing Metadata

Form type
4
Filed
Jan 20, 7:00 PM ET
Accepted
Jan 21, 5:23 PM ET
Size
9.1 KB